title: [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for multiple myeloma].
abstract: Recent meta-analyses and systematic reviews focusing on the significance of high dose therapy with autologous hematopoietic stem cell transplantation for newly-diagnosed multiple myeloma patients have shown its benefit in terms of progression-free survival, but no over-all survival benefit versus conventional chemotherapy. New drug-containing regimens, with agents such as iMIDs and proteasome inhibitors, have not yet been established as high-dose therapy, because no phase III RCT has been conducted to date. Although several guidelines recommend maintenance therapy for non-CR patients after transplantation, caution is still warranted because the JSH guideline advocates further careful discussion of this clinical question.
authors: Department of Hematology, Ogaki Municipal Hospital.
authors: Hiroshi
authors: H
authors: Kosugi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D014182:Transplantation, Autologous / Q000379:methods